Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.

Precipio, Inc.

Monday, April 21, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), ServiceNow, Inc. (NOW) and The Progressive Corp. (PGR), as well as two micro-cap stocks The Monarch Cement Co. (MCEM) and Precipio, Inc. (PRPO). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Expect the Unexpected for a New Trading Week
Today's Featured Research Reports
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+20.3% vs. +15.9%). The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving revenues. It expects net revenues to grow by low double-digits in fiscal 2025.
Visa is fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
However, elevated operating expenses pose margin challenges. We expect this metric to rise 7.6% year over year in fiscal 2025. It is witnessing volatile cash volume from the Asia Pacific and U.S. regions. Hence, the stock warrants a cautious stance.
(You can read the full research report on Visa here >>>)
Shares of ServiceNow have outperformed the Zacks Computers - IT Services industry over the past year (+4.7% vs. -5.1%). The company has been benefiting from the rising adoption of its workflows by enterprises undergoing digital transformation.
ServiceNow had 2,109 total customers with more than $1 million in annual contract value (ACV) at the end of the fourth quarter, which represents 14% year-over-year growth in customers. ServiceNow had 19 deals greater than $5 million in net new ACV. It closed 170 deals greater than $1 million net new ACV. Generative Artificial Intelligence (Gen AI) deals continued to gain traction.
ServiceNow is extensively leveraging AI and machine learning technologies to boost the potency of its solutions. Pro Plus AI grew 150% sequentially. It is riding on an expanding partner base and acquisitions. However, NOW is suffering from stiff competition and unfavorable forex.
(You can read the full research report on ServiceNow here >>>)
Progressive’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+25.9% vs. +23.9%). The company continues to gain on higher premiums, given its compelling product portfolio, leadership position and strength in both Vehicle and Property businesses.
Progressive’s focus on becoming a one-stop insurance destination, catering to customers opting for a combination of home and auto insurance, augurs well for the company's growth. Policies in force and retention ratio should remain healthy. Competitive pricing to retain current customers and address customer needs with new offerings should continue to drive policy life expectancy.
However, exposure to catastrophe losses induces underwriting volatility. Escalating expenses due to higher losses and settlement expenses remain an overhang on the margin. Its high debt level induces higher interest expense concerns.
(You can read the full research report on Progressive here >>>)
Shares of Monarch Cement have outperformed the Zacks Building Products - Concrete and Aggregates industry over the past year (+29.7% vs. -12.2%). This microcap company with market capitalization of $856.63 million offers a compelling case for long-term investors with steady fiscal 2024 growth, driven by effective pricing that offset volume declines.
Net sales rose 2% year over year to $268.1 million, with gross profit up 6.7% and cement margins expanding to 52.4%. Strong internal cash generation of $73.6 million supported consistent dividends, including a $2.17 special payout. Retained earnings climbed 13.1% to $368.5 million, boosting equity to $403.9 million and reinforcing capital strength.
Monarch Cement remains debt-free, with $48.8 million in cash and access to $15 million in credit. Its regional footprint and dual revenue streams add diversification, while long-term raw material reserves support sustainable production. A new JV enhances downstream exposure and capital flexibility. Monarch Cement’s brand, balance sheet, and strategic initiatives underscore its durability and income appeal.
(You can read the full research report on Monarch Cement here >>>)
Precipio’s shares have outperformed the Zacks Medical Info Systems industry over the year-to-date period (+11.7% vs. -5.2%). This microcap company with a market capitalization of $8.85 million is transitioning from capital preservation to a growth-oriented, self-funded model, driven by its profitable Pathology division, which exceeded its $1.3 million per month breakeven for two straight quarters, and targets a $25 million run-rate by 2025.
The Products unit, flat in fourth-quarter 2024, is poised for growth via leadership changes, major client onboarding and a revamped distribution strategy, aiming to double revenue to $5.6 million. Precipio’s strategic execution, disciplined spending, capital-light model and alignment with precision diagnostics trends support long-term potential.
Risks include fragile liquidity, execution delays, regulatory shifts, customer concentration and macroeconomic headwinds that could pressure growth and margins. The stock appears undervalued, signaling an entry point for value-oriented investors.
(You can read the full research report on Precipio here >>>)
Other noteworthy reports we are featuring today include Toyota Motor Corp. (TM), GSK plc (GSK) and Paychex, Inc. (PAYX).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Visa (V) Rides On Cross Border Volume Growth, Expenses High
Growing Customer Base Drives ServiceNow's (NOW) Prospects
Progressive's (PGR) Solid Policies in Force Aid, Cat Loss Ail
Featured Reports
Surge in Hybrid Adoption Aids Toyota (TM), High Expenses Ail
Per the Zacks analyst, continued growth in hybrid adoption is likely to boost Toyota's sales. However, high R&D expenses on advanced technologies are likely to limit the near-term margins.
GSK (GSK) Specialty Medicines Unit Strong; Vaccines Weak
GSK is witnessing increased sales growth of the Specialty Medicines unit. However, slowing sales in the Vaccines unit concerns the Zacks analyst
Paychex (PAYX) Gains on Flexible Portfolio Despite Expenses
Per the Zacks analyst, Paychex's ability to meet clients' HR and payroll needs through a comprehensive and flexible service portfolio benefits its top line. Rising expenses are concerning.
Southwest Airlines (LUV) Rides on Air Travel Demand, Costs Ail
The Zacks Analyst likes LUV's revenue management actions, which are likely to boost revenue growth and expand the customer base. However, the rise in labor costs weighs on bottom-line growth.
Smart Water Innovation & Buyouts Drive Badger Meter (BMI)
Per the Zacks analyst, Badger Meter's performance is driven by its customer-focused innovation, and strategic agility. SmartCover acquisition is paying off early with positive feedback from customers.
Amedisys (AMED) Rides on Key Metric, Merger Woes Persist
Per the Zacks analyst, Amedisys achieving the Quality of Patient Care star average of 4.18 across all providers, is impressive. Yet, legal hurdles cloud its proposed merger with UnitedHealth Group.
Transocean Buoyed by Strong Backlog and Utilization
The Zacks analyst notes that Transocean's $7.9 billion backlog and near-full fleet utilization boost revenue visibility, but its high debt remains a concern.
New Upgrades
Solid Demand Across Data Center Market Aid Marvell (MRVL)
Per the Zacks Analyst, Marvell is growing on solid momentum in electro-optics products, custom silicon, storage and switch divisions, which are driving the Data Center end-market revenues.
Loans, Dealer Enrolments to Support Credit Acceptance (CACC)
Per the Zacks analyst, decent loan demand, rising dealer enrollments, a high cash flow-generating business model, and a solid balance sheet will likely aid Credit Acceptance's financials.
Advance Technology, Acquisitions Aid Consolidated Water (CWCO)
Per the Zacks analyst, Consolidated Water uses most advanced technology for desalination, allowing it to benefit by meeting increasing demand. Strategic acquisitions will boost its performance.
New Downgrades
American Eagle's (AEO) Soft FY25 View Indicates More Troubles
Per the Zacks analyst, American Eagle is expected to face headwinds in fiscal 2025 from consumer trends and macroeconomic climate, despite measures taken to reinforce sales and lower expenses.
Soft Comps & Macro Woes Ail Dave & Buster's (PLAY) Prospects
Per the Zacks analyst, Dave & Buster's is likely to be hurt by a drop in comps and store renovation disruptions. Also, an uncertain tariff environment is a concern.
Increasing Costs and Forex Woes to Hurt Zebra Technologies
Per the Zacks analyst, Zebra Technologies is struggling with high operating costs and expenses, which in turn, are hurting the company's bottom line. Forex woes are an added concern.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report
Visa Inc. (V) : Free Stock Analysis Report
Toyota Motor Corporation (TM) : Free Stock Analysis Report
Paychex, Inc. (PAYX) : Free Stock Analysis Report
The Progressive Corporation (PGR) : Free Stock Analysis Report
ServiceNow, Inc. (NOW) : Free Stock Analysis Report
Precipio, Inc. (PRPO) : Free Stock Analysis Report
The Monarch Cement Co. (MCEM): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Research Reports for Visa, ServiceNow & Progressive

For Immediate Release
Chicago, IL – January 16, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. V, AbbVie Inc. ABBV, Analog Devices, Inc. ADI and Precipio, Inc. PRPO.
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Visa, AbbVie and Analog Devices
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., AbbVie Inc. and Analog Devices, Inc., as well as a micro-cap stock Precipio, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past six months (+15.2% vs. +14.7%). The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving revenues. The company, fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth.
The Zacks analyst expects revenues to grow 9.1% in fiscal 2025. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
However, elevated operating expenses pose margin challenges. We expect adjusted operating expenses to jump 8.1% in fiscal 2025. It is witnessing a volatile cash volume from the Asia Pacific and U.S. regions. Consumer spending growth is also drying up. Moreover, rising client incentives will affect its adjusted revenues.
(You can read the full research report on Visa here >>>)
Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+11.7% vs. -2.2%). The company has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq. The drugs are performing extremely well, bolstered by approvals in new indications.
AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. AbbVie has been on an acquisition spree lately in its core space of immunology.
However, the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth for Juvederm fillers in the United States and China. AbbVie’s shares have outperformed the industry in the past year. Estimates have declined slightly ahead of Q4 earnings.
(You can read the full research report on AbbVie here >>>)
Analog Devices’ shares have outperformed the Zacks Semiconductor - Analog and Mixed industry over the past year (+16.3% vs. +0.2%). The company is benefiting from strong momentum across the consumer and automotive end markets. Strong momentum across the electric vehicle space on the back of its robust Battery Management System solutions remains a tailwind.
Strong investments in technology and business innovation are contributing well. The solid momentum of the HEV platform across the cabin electronics ecosystem is positive.
Nonetheless, the weak demand environment across multiple end markets remains a major concern. The sluggish communications market due to the broad-based inventory corrections is a major negative. Broad-based weakness in the industrial end market remains a headwind. The ongoing inventory correction is expected to be a headwind for the company in the near term.
(You can read the full research report on Analog Devices here >>>)
Shares of Precipio have outperformed the Zacks Medical Info Systems industry over the past year (+15.0% vs. -12.1%). This microcap company with market capitalization of $8.98 million have achieved breakeven in its Pathology arm for two consecutive quarters in 2024, generating $4.6 million in third-quarter revenues, up 17.7% from the second quarter. Its $20 million annual run rate provides stable cash flow to fund R&D without external capital, highlighting operational efficiency.
The Products arm, with 13.9% third-quarter revenue growth, is poised as a high-margin growth engine, leveraging scalable distribution channels. Cash burn fell 75% year over year to $226,000 in the third quarter, supporting financial stability and non-dilutive growth.
Precipio’s focus on diagnostics innovation, digital transformation and market visibility aligns with precision medicine trends. Risks include Products underperformance, reliance on small sales teams, distributor dependency, competitive pressures, macroeconomic factors and regulatory uncertainties.
(You can read the full research report on Precipio here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Analog Devices, Inc. (ADI) : Free Stock Analysis Report
Visa Inc. (V) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Precipio, Inc. (PRPO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Analyst Blog Highlights Visa, AbbVie, Analog Devices and Precipio

Wednesday, January 15, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Analog Devices, Inc. (ADI), as well as a micro-cap stock Precipio, Inc. (PRPO). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past six months (+15.2% vs. +14.7%). The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving revenues. The company, fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth.
The Zacks analyst expects revenues to grow 9.1% in fiscal 2025. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
However, elevated operating expenses pose margin challenges. We expect adjusted operating expenses to jump 8.1% in fiscal 2025. It is witnessing a volatile cash volume from the Asia Pacific and U.S. regions. Consumer spending growth is also drying up. Moreover, rising client incentives will affect its adjusted revenues.
(You can read the full research report on Visa here >>>)
Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+11.7% vs. -2.2%). The company has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq. The drugs are performing extremely well, bolstered by approvals in new indications.
AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. AbbVie has been on an acquisition spree lately in its core space of immunology.
However, the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth for Juvederm fillers in the United States and China. AbbVie’s shares have outperformed the industry in the past year. Estimates have declined slightly ahead of Q4 earnings.
(You can read the full research report on AbbVie here >>>)
Analog Devices’ shares have outperformed the Zacks Semiconductor - Analog and Mixed industry over the past year (+16.3% vs. +0.2%). The company is benefiting from strong momentum across the consumer and automotive end markets. Strong momentum across the electric vehicle space on the back of its robust Battery Management System solutions remains a tailwind.
Strong investments in technology and business innovation are contributing well. The solid momentum of the HEV platform across the cabin electronics ecosystem is positive.
Nonetheless, the weak demand environment across multiple end markets remains a major concern. The sluggish communications market due to the broad-based inventory corrections is a major negative. Broad-based weakness in the industrial end market remains a headwind. The ongoing inventory correction is expected to be a headwind for the company in the near term.
(You can read the full research report on Analog Devices here >>>)
Shares of Precipio have outperformed the Zacks Medical Info Systems industry over the past year (+15.0% vs. -12.1%). This microcap company with market capitalization of $8.98 million have achieved breakeven in its Pathology arm for two consecutive quarters in 2024, generating $4.6 million in third-quarter revenues, up 17.7% from the second quarter. Its $20 million annual run rate provides stable cash flow to fund R&D without external capital, highlighting operational efficiency.
The Products arm, with 13.9% third-quarter revenue growth, is poised as a high-margin growth engine, leveraging scalable distribution channels. Cash burn fell 75% year over year to $226,000 in the third quarter, supporting financial stability and non-dilutive growth.
Precipio’s focus on diagnostics innovation, digital transformation and market visibility aligns with precision medicine trends. Risks include Products underperformance, reliance on small sales teams, distributor dependency, competitive pressures, macroeconomic factors and regulatory uncertainties.
(You can read the full research report on Precipio here >>>)
Other noteworthy reports we are featuring today include UnitedHealth Group Inc. (UNH), Constellation Energy Corp. (CEG) and Equinor ASA (EQNR).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Visa (V) Rides on Increasing Payments Volume, Expenses High
AbbVie's (ABBV) Skyrizi, Rinvoq Key to Top-Line Growth
Analog Devices (ADI) Gains From Traction in its Automotive Products
Featured Reports
UnitedHealth (UNH) to Ride on UnitedHealthcare & Optum Units
Per the Zacks analyst, UnitedHealth's strong performance in UnitedHealthcare and Optum businesses will lead to increased profits. Yet, rising operating expenses remain a concern.
Focus on Renewable Energy Aid Constellation Energy (CEG)
Per the Zacks analyst, Constellation Energy gains from expansion of renewable portfolio. Its position as an industry leader in the safe operation of nuclear plants helps it increase its nuclear output
Investment in Clean Assets Aid Public Service Enterprise (PEG)
Per the Zacks analyst, Public Service Enterprise makes investments to strengthen its infrastructure and expand renewable assets, which are going to boost its operation.
Corning (GLW) Rides on Healthy Demand & Product Innovation
Per the Zacks analyst, the growing adoption of innovative optical connectivity products for generative AI applications and strong demand for Gorilla Glass will likely drive Corning's top line.
Waters' (WAT) Rides on Strong Demand for Testing Solutions
Waters is benefiting from an expanding portfolio, improving pharma spending bodes and strong demand for flagship HPLC product.
Aerospace Segment & MB Aerospace Buyout Drives Barnes (B)
Per the Zacks analyst, Barnes is witnessing strength in the Aerospace aftermarket unit, fueled by higher airline traffic & aircraft utilization. The MB Aerospace buyout contributes strongly to growth.
Potential in BioReference Business Aids OPKO Health (OPK)
The Zacks analyst is upbeat about OPKO Health's strength in BioReference Health, offering comprehensive laboratory testing services, despite its operation in a highly competitive space.
New Upgrades
Equinor's (EQNR) Focus on Renewable Energy Expansion Aids
The Zacks analyst believes that Equinor's expansion in the renewables and low-carbon energy sector should create new revenue streams in the growing market for clean energy.
Extensive Footprint & Omnichannel Efforts Aid Carmax (KMX)
Per the Zacks analyst, CarMax's extensive nationwide footprint and logistics network provides it a competitive advantage. Omnichannel initiatives are set to boost its long-term efficiencies.
Loan Diversification, Rising Deposit Aid First Horizon (FHN)
Per the Zacks analyst, First Horizon's organic growth is supported by its diversified loan portfolio. Additionally, the rising deposit balance further contributes to top-line expansion.
New Downgrades
Freight Demand Weakness Hurts Werner's (WERN) Prospects
The Zacks analyst is concerned about Werner's below-par revenues due to weak freight demand. Driver shortage represents another headwind for WERN.
Signet (SIG) Struggles with Fashion Gifting as Comps Decline
Per the Zacks analyst, Signet saw a drop in same-store sales, with the fashion gifting segment underperforming due to shifting consumer preferences for lower-priced items. The company cut the Q4 view.
High Expenses & Market Risks Ail Builders FirstSource (BLDR)
Per the Zacks analyst, Builders FirstSource is hurting from a reduced operating leveraging resulting in high expenses. Moreover, the inflationary pressures and market fluctuations are adding to it.
Free Today: Profiting from The Future’s Brightest Energy Source
The demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.
Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.
Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Analog Devices, Inc. (ADI) : Free Stock Analysis Report
Visa Inc. (V) : Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Constellation Energy Corporation (CEG) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Precipio, Inc. (PRPO) : Free Stock Analysis Report
Equinor ASA (EQNR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Research Reports for Visa, AbbVie & Analog Devices

Health care stocks were declining in late Wednesday afternoon trading, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down 0.3%.
The iShares Biotechnology ETF (IBB) fell 1%.
In corporate news, Allakos (ALLK) shares slumped more than 11% following analyst downgrades in the wake of a setback in the trials of lirentelimab in people with atopic dermatitis and chronic spontaneous urticaria.
KKR-backed (KKR) BrightSpring Health Services said Wednesday it has launched its initial public offering, with a listing expected on the Nasdaq Global Select Market. KKR shares were shedding 0.5%.
Precipio (PRPO) jumped 16% after the company signed an agreement with a Japanese distributor to sell its products in Japan.
Natera (NTRA) gained 7.3%. The company said it plans to file an appeal after a jury reached a verdict in the US District Court for the Western District of Texas over a patent infringement lawsuit brought by Ravgen.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Health Care Sector Update for 01/17/2024: ALLK, KKR, PRPO, NTRA

The average one-year price target for Precipio (NASDAQ:PRPO) has been revised to 40.80 / share. This is an increase of 1,900.00% from the prior estimate of 2.04 dated August 31, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 40.40 to a high of 42.00 / share. The average price target represents an increase of 567.76% from the latest reported closing price of 6.11 / share.
What is the Fund Sentiment?
There are 25 funds or institutions reporting positions in Precipio. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to PRPO is 0.00%, an increase of 10.46%. Total shares owned by institutions increased in the last three months by 112.79% to 4,771K shares. The put/call ratio of PRPO is 0.00, indicating a bullish outlook.
What are Other Shareholders Doing?
Walleye Capital holds 2,325K shares representing 168.72% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 662K shares representing 48.04% ownership of the company. No change in the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 353K shares representing 25.61% ownership of the company. No change in the last quarter.
Geode Capital Management holds 257K shares representing 18.62% ownership of the company. No change in the last quarter.
FSMAX - Fidelity Extended Market Index Fund holds 123K shares representing 8.89% ownership of the company. In it's prior filing, the firm reported owning 125K shares, representing a decrease of 1.64%. The firm decreased its portfolio allocation in PRPO by 26.18% over the last quarter.
Precipio Background Information
(This description is provided by the company.)
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	0.00 23.75
Price/Sales	0.51 3.01
P/B	0.74 2.20
P/FCF	0.00 18.30

Indicator	TTM Median
ROE	-23.08 25.41
ROA	-16.90 6.00
Net Worth	0.01 0.20
Quick Ratio	0.59 1.71
Current Ratio	0.73 2.83

Indicator	TTM Median
EPS	0.42 0.37
EPS Forecast	0.00 0.37
Revenue	4.00M 16.00M
Gross Profit	2.00M —
EBITDA	-1.00M —

Precipio, Inc.

Fundamental PRPO

Valuation

Debts

Efficiency

Other ratios

Revenue